（记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：公司的外骨骼机器人开始临床试验了吗？ 新华医疗（600587.SH）12月4日在投资者互动平台表示，2025年1月26日，公司下肢助行外骨骼机器人 收到国家知识产权局专利申请受理通知书。目前医院级产品现处于功能样机研发阶段，预计2026年完成 产品研发，2027年取得医疗器械注册证，该产品支持医院、社区、家庭及养老机构等多场景应用。 ...

每经AI快讯，有投资者在投资者互动平台提问：请问在外骨骼机器人方面，公司对发展前景如何看 待？投入情况和取得成果，请简单介绍下。 （文章来源：每日经济新闻） 新华医疗（600587.SH）12月4日在投资者互动平台表示，随着国内人口老龄化程度的不断加深，康复 需求持续增长，下肢外骨骼康复机器人作为康复机器人市场的重要组成部分，其市场份额也在不断扩 大。近年来，随着医疗行业的快速发展，国家出台了一系列政策、法律和法规，也为下肢外骨骼康复机 器人的发展提供了重要的政策支持和保障。公司高度重视外骨骼机器人的发展，已组建涵盖机械、控 制、康复医学等多学科的专业研发团队，并持续投入研发资源。截至目前，已在外骨骼结构轻量化、关 节驱动控制、步态轨迹生成等关键技术上实现突破，为产品化奠定了扎实基础。 ...

Core Viewpoint - The company reported a slight increase in total revenue by 6.00% year-on-year, but net profit significantly decreased by 42.89% year-on-year, primarily due to increased R&D expenses of 126 million yuan, which rose by 20.15% year-on-year [2]. Group 1: Financial Performance - Total revenue increased by 6.00% year-on-year [2]. - Net profit decreased by 42.89% year-on-year [2]. - R&D expenses amounted to 126 million yuan, reflecting a year-on-year increase of 20.15% [2]. Group 2: R&D Focus - The company emphasizes research and development as a key driver for product innovation and upgrades [2]. - The strategic R&D direction focuses on applications in rehabilitation medicine, including brain-machine interfaces, exoskeleton robots, and artificial intelligence (AI) [2]. - The establishment of the Rehabilitation Robot Laboratory and Sun-BCI Lab for brain science indicates a commitment to advancing brain-machine interface technology [2]. - A significant portion of R&D investment is directed towards areas directly or indirectly related to brain-machine interface technology [2].

Market Overview - Major indices opened higher with Shanghai Composite Index up 0.10%, Shenzhen Component Index up 0.37%, and ChiNext Index up 0.60% [1] - The storage, HBM, and power grid sectors showed significant gains [1] Index Performance - Shanghai Composite Index: 3973.35, up 0.10%, with a trading volume of 83.35 billion [2] - Shenzhen Component Index: 13272.47, up 0.37%, with a trading volume of 101.14 billion [2] - ChiNext Index: 3185.13, up 0.60%, with a trading volume of 41.02 billion [2] External Market Influences - U.S. stock indices experienced slight gains, with S&P 500 up 0.37%, Nasdaq up 0.65%, and Dow Jones up 0.48% [3] - Chinese concept stocks rebounded, with notable performances from Alibaba, JD.com, and NIO, while Pinduoduo and others also showed mixed results [3] Sector Insights - Citic Securities anticipates multiple factors will likely drive gold prices upward, influenced by geopolitical tensions and U.S. economic performance [4] - CITIC Construction believes the medical device sector is at a turning point, with opportunities for valuation and performance recovery, especially in respiratory testing and home device sales [5] - China Merchants Securities highlights strong performance in the securities industry, with a year-on-year increase in revenue and net profit for listed brokerages [6] - CICC is optimistic about the recovery in the restaurant and tourism sectors, expecting policy expansion to boost demand [7][8]

Group 1: Market Overview - The market experienced a rebound with all three major indices closing in the green, with the Shanghai Composite Index up 0.23%, the Shenzhen Component Index up 0.37%, and the ChiNext Index up 1.03% [1] - The total trading volume in the Shanghai and Shenzhen markets was 1.87 trillion yuan, a decrease of 45.3 billion yuan compared to the previous trading day [1] Group 2: Medical Device Sector - CITIC Securities believes that the medical device sector is at a turning point, with both valuation and performance undergoing recovery [2] - The upcoming flu season in Q4 presents opportunities in respiratory testing-related businesses, and online sales trends for home medical devices during "Double 11" should be monitored [2] - There are expected performance and valuation recovery opportunities for companies projected to improve by 2026, with several leading firms in the medical device sector anticipated to experience accelerated growth [2] - Long-term investment opportunities in the medical device industry stem from innovation, international expansion, and mergers and acquisitions, with a focus on innovative device sectors and technologies such as brain-computer interfaces and surgical robots [2] Group 3: Renewable Energy Sector - Guojin Securities confirms that the bottoming out of the renewable energy sector is evident, with a recovery in the photovoltaic and energy storage sectors, and a 9.7 GW increase in new installations in September [3] - The hydrogen energy sector is also showing signs of recovery, with Bloom achieving profitability in Q3 and significant cost reductions in SOFC [3] - The electricity grid sector is benefiting from government initiatives to enhance energy channels and accelerate smart grid construction, with a reported revenue of 93.6 billion yuan and a net profit of 8.2 billion yuan in Q3, reflecting year-on-year growth of 10% and 15% respectively [3] Group 4: Catering and Tourism Sector - CICC anticipates a stabilization in the social service industry in 2025 after experiencing price pressures and declines in same-store sales in 2024, with signs of bottoming out [4] - The focus for 2026 should be on the recovery of domestic demand and policy expansion, particularly for comprehensive leading companies with strong growth potential [4] - In the catering sector, attention should be paid to high-quality brands that are expected to achieve stable performance growth despite competitive pressures [4] - The hotel industry is expected to see a rebalancing of supply and demand, with a potential turning point for RevPAR contingent on the recovery of business demand [4]

Investment Rating - The report gives a "Buy" rating for the company, indicating a positive outlook for the stock price over the next six months [4]. Core Insights - The company is a leader in carbon fiber technology with a significant market share exceeding 60% in China, and it has a production capacity of over 1,000 tons annually [1]. - The carbon fiber equipment business is expected to generate revenue of 629 million yuan in the first half of 2025, accounting for 59.31% of total revenue, reflecting a year-on-year growth of 59.53% [1]. - The company is actively expanding into new applications such as exoskeleton robots and PEEK materials, which are expected to create a second growth curve [2]. - Revenue projections for 2025-2027 are estimated at 2.198 billion yuan, 2.763 billion yuan, and 3.440 billion yuan, respectively, with corresponding net profits of 293 million yuan, 393 million yuan, and 530 million yuan [2]. Summary by Sections Carbon Fiber Equipment - The company has achieved significant technological breakthroughs in carbon fiber production, with the maximum capacity of carbonization lines increased from 3,000 tons to 5,000 tons [1]. - The company is investing in high-performance fiber projects and has established composite material companies in Shaoxing and Wuhan [1]. Exoskeleton Robots and New Applications - The second generation of the company's exoskeleton robot has completed testing and is expected to enter mass production [2]. - The company is exploring new application scenarios for carbon fiber combined with PEEK materials, focusing on high-value cross-industry integration [2]. Financial Projections - The company anticipates a revenue growth rate of 27.14% in 2025, followed by 25.72% in 2026 and 24.51% in 2027 [3]. - The projected net profit growth rates are 99.20% for 2025, 34.18% for 2026, and 34.86% for 2027 [3].

Summary of Key Points from the Conference Call on the Medical Device Industry Industry Overview - The Chinese medical device industry has significant potential for domestic substitution, with certain segments still having room for improvement in localization rates [1][3][10] - Chinese companies are positioned to become global leaders in the context of globalization, leveraging strong innovation capabilities and manufacturing advantages [1][4][10] Core Insights and Arguments - The high-value consumables sector is expected to see a notable recovery by 2025, with investment opportunities in orthopedics, neurointervention, ophthalmology, and electrophysiology [1][5] - Companies such as Huatai Medical, MicroPort, Lepu Medical, Mindray, and United Imaging are highlighted for their growth potential [1][5] - The upstream medical device sector is experiencing a turning point, with companies like Meihua Medical and Yirui Technology poised for significant revenue growth due to innovative products [1][6] - The in vitro diagnostics (IVD) sector has faced challenges due to policy impacts, but a recovery is anticipated next year, with New Industry expected to see positive revenue growth in Q4 [1][7] - Strategic adjustments by Chinese medical device companies include cost reduction, technological innovation, transformation to consumer-oriented businesses, and overseas market expansion [1][9] Additional Important Insights - The global medical device market is approximately 4 to 5 times larger than China's market, which is projected to grow significantly [2][12] - Chinese companies are diversifying their overseas expansion strategies, which include R&D innovation, clinical registration, and patent layout to mitigate geopolitical risks [2][11][14] - The importance of innovation is emphasized as a key driver for growth, with a focus on new product development and emerging technologies such as AI and brain-computer interfaces [26][31] - The medical device industry is witnessing a trend towards mergers and acquisitions as a means for companies to enhance their product lines and market positions [33][36] Notable Companies and Their Strategies - Mindray Medical is leading in internationalization, with overseas revenue expected to reach 45% in 2024 [19] - United Imaging and BGI are also making significant strides in their respective markets, with notable growth in overseas business [19][24] - High-value consumables companies like Nanwei Medical and MicroPort are employing various strategies, including direct sales and ODM, to expand their international presence [21][22] Future Outlook - The medical device industry is expected to continue evolving, with significant opportunities in areas such as AI healthcare applications, home respiratory devices, and surgical robots [28][30] - The brain-computer interface technology is emerging as a key investment area, with China positioned as a global leader [31] - The overall sentiment is optimistic regarding the recovery and growth potential of the Chinese medical device market, particularly as companies adapt to changing market conditions and consumer demands [36]

Group 1 - The article highlights the top 10 open-end funds with the highest net value growth as of September 16, 2025, including 德邦高端装备混合发起式C and 德邦高端装备混合发起式A, which showed significant increases in net value [2][6] - The net value of 德邦高端装备混合发起式C increased from 1.1635 to 1.2649, reflecting a growth of 8.00% [2] - The article also mentions the bottom 10 funds, with 银华国证港股通创新药ETF showing a decline in net value from 1.5532 to 1.5070, a decrease of 2.00% [4][6] Group 2 - The analysis indicates that the Shanghai Composite Index opened high but later experienced fluctuations, with a total trading volume of 2.36 trillion, and a market breadth of 3629 gainers to 1689 losers [6] - Leading sectors included comprehensive and IT equipment industries, both showing gains exceeding 3% [6] - The fund strategy analysis suggests that the 德邦高端装备混合发起式C fund is focused on the general machinery industry, with a significant portion of its holdings in companies like 汉威科技 and 银轮股份, which saw substantial daily increases [7]

Group 1 - Exoskeleton robots are becoming a standard feature in both domestic and international sci-fi films, showcasing their potential in enhancing human capabilities [1] - The exoskeleton robot is a wearable intelligent mechanical device that enhances or replaces human movement abilities, inspired by the exoskeleton structure of insects [1] - Shanghai Aoshark Intelligent Technology Co., Ltd. is the developer of these robots and has supported the filming of the entire "The Wandering Earth" series, with plans to upgrade technology for "The Wandering Earth 3" [1] Group 2 - The company's first consumer-grade product, the Aoshark Viatrix exoskeleton robot, enhances leg strength and reduces physical exertion, with a single battery supporting a maximum range of 25 kilometers [1] - The FIT-HV intelligent electric waist exoskeleton robot is an industrial-grade assistive device designed to reduce the load on workers' lower backs, featuring three working modes for efficient lifting and walking support [2] - The FIT-HV device is easy to wear, similar to putting on a backpack, and activates with a simple switch to provide assistance [2]

Group 1 - The article discusses the rising popularity of exoskeleton robots, which are wearable intelligent mechanical devices designed to enhance or replace human movement capabilities, inspired by the exoskeleton structure of insects [1] - Shanghai Aoshark Intelligent Technology Co., Ltd. is highlighted as a key developer of exoskeleton robots, having supported the filming of the "The Wandering Earth" series and planning to upgrade technology for the upcoming "The Wandering Earth 3" [1] - The company's first consumer product, the Aoshark Viatrix exoskeleton robot, is designed for various activities such as walking, running, and climbing, providing leg strength enhancement and reducing physical energy consumption, with a single battery supporting up to 25 kilometers of range [1] Group 2 - The FIT-HV intelligent electric waist exoskeleton robot is introduced as an industrial-grade assistive device aimed at reducing the load on workers' lower backs, featuring three working modes and easy wearability similar to carrying a backpack [2] - The FIT-HV device is designed to provide efficient lifting assistance and walking support, enhancing worker productivity and comfort [2]